GlobalData analysed the number of clinical trials examining triple-negative breast cancer (TNBC) with start dates between 1 January 2009 and 11 December 2019.
TNBC is a form of breast cancer that is not stimulated by estrogen, progesterone or the HER2 protein.
Approximately 10–20% of breast cancers are triple-negative, as they fail to test for estrogen receptors, progesterone receptors or excess HER2 protein. Typically, TNBC fails to respond to normal hormonal therapy. However, other immunotherapies can be used to treat the condition.
Figure 1 shows the TNBC trials that GlobalData analysed by phase. The majority of TNBC trials were in Phase II (59%), followed by Phase I (26.0%), Phase III (9%), and Phase IV (3 %).
Figure 2 shows the top five countries that are conducting TNBC trials. The US had the most trials with 79.5%, whereas Spain had 6.9%, France had 5.7%, Germany had 4.1%, and Italy had 3.8%. Most of these trials were led by non-industry sponsors (57.9%).